pharmaphorum

FEBRUARY 11, 2021

Pharma companies face many challenges when involving patients in the design of clinical trials – but doing so can have huge benefits further down the line, improving the sustainability and quality of research. The NIHR is also embedded in the NHS, perhaps the most trusted institution in the UK.

Clinical Trials 101

Clinical Trials Clinical Trials Trials Clinical Research 101

pharmaphorum

JULY 5, 2021

Parexel has been a champion of the concept for years, but while adoption was fairly slow pre-COVID, it has accelerated at a fast pace since the crisis, aided by the increasing willingness of regulators to accept decentralised trial data in marketing applications.

Clinical Trials 64

Clinical Trials Clinical Trials Trials Regulation 64

pharmaphorum

MARCH 12, 2021

That was the message from ‘The New Normal: Balancing the rapid evolution of trial design with patient need’ panel at the NIHR’s Clinical Research Network Virtual Event on Delivering Complex and Innovative Design (CID) Studies. Thankfully, many pharma companies seem to be gradually improving on this.

Trials 132

Trials Research Pharma Companies Clinical Trials 132

pharmaphorum

JUNE 8, 2021

Dr Jay Mei from Antengene tells us how the Asia Pacific region is opening up to innovative pharma companies, and gives tips for companies navigating this enormous market. At the same time, lots of people with experience at multinational pharmaceutical companies have chosen to return home.

Marketing 105

Marketing Drugs Development Regulation 105

XTalks

MARCH 28, 2024

The FDA’s approval of Duvyzat for DMD, based on our robust and successful clinical development program, reflects Italfarmaco’s commitment to providing a safe and proven-effective therapy that can have a meaningful impact for people living with DMD,” said Paolo Bettica, MD, PhD, chief medical officer at Italfarmaco Group in a press release.

FDA Approval 105

FDA Approval Genetics Gene Therapy Gene 105

pharmaphorum

NOVEMBER 3, 2022

As we strive to improve the medical product development process and speed the development of effective new therapies to patients, digital health solutions are becoming increasingly available, affordable, and anticipated in healthcare settings by patients, clinicians, and caregivers alike, driving expectations for trial participants.

Clinical Trials 81

Clinical Trials Clinical Trials Trials Medicine 81

XTalks

SEPTEMBER 5, 2023

Xtalks spoke with Maria Reyes Boceta-Muñoz, Clinical Operations Head of Development R&D at GlaxoSmithKline in Spain, Portugal & Israel, to understand the current vaccine development climate and where the sector is headed. It is affected by factors such as complacency, convenience, confidence and cultural factors.

Vaccination 96

Vaccination Vaccine Development Clinical Trials 96

pharmaphorum

APRIL 7, 2021

With other drugs in the pipeline too, van de Winkel said the company aims to continue to break new ground with next-generation antibody-based therapies. He notes that it already has 21 partnerships with pharma companies and will aim to keep more product rights than it did in the past. In good shape. We are in a crisis.

Antibody 91

Antibody Life Science Development Drugs 91

pharmaphorum

APRIL 28, 2022

Although they have, by definition, small addressable markets, the treatments cost just as many resources to develop as therapies for more common diseases – sometimes more, because of the added difficulty of finding sufficiently large patient populations for trials and finding disease experts to run them. How big pharma tackles rare diseases.

Pharma Companies 59

Pharma Companies Branding Development Marketing 59

pharmaphorum

MARCH 2, 2022

The pharma company was quick to point out however that the CLOVER trial of PF-06425090 was undermined by a lower-than expected rate of C. diff since Sanofi ended development of its candidate in 2017, ahead of Valneva whose VLA84 has been shelved after phase 2 while it looks for a development partner.

Vaccination 52

Vaccination Vaccine Trials Bacterium 52

pharmaphorum

MAY 21, 2021

It builds on the company’s four partnership projects: two with the generics and biosimilars firm Hikma, one with US biotech Inhibrix and another with an unnamed biosimilars partner. Regulators may not require the large phase 3 trials needed to approve completely new drugs, as safety is proven.

Insulin 52

Insulin Drugs Production Marketing 52

pharmaphorum

MAY 14, 2021

That may depend on funding, trial results and whether a big pharma decides to partner with MoonLake in the future to help take the drug into late-stage development and launch it. It’s extremely possible a pharma company may want to partner and it can have many forms. is the future in inflammatory diseases.”.

Drugs 66

Drugs Licensing Licensing Development 66

The Pharma Data

DECEMBER 17, 2020

Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs. Prior to Fulcrum, Cadavid held several leadership positions at Biogen, including Senior Medical Director of the multiple sclerosis clinical development group. Immune Regulation – U.K.-based

Development 52

Development Gene Therapy Engineer Life Science 52

Delveinsight

AUGUST 17, 2020

million in 2019 and is anticipated to increase at a CAGR for the study period 2017-2030 owing to dynamic pipeline therapies in the mid-/ late-stage clinical development and rising gastroparesis prevalence. Gastroparesis Market: Influx of Pharma players and novel pipeline therapies.

Marketing 54

Marketing Trials FDA Approval Clinical Development 54

XTalks

MAY 6, 2022

In this interview, Xtalks spoke with experts from eClinical Solutions , Katrina Rice, Chief Delivery Officer, Data Services; and Diane Lacroix, Vice President, Clinical Data Management, about clinical data management for modern day digital clinical trials.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Life Science 98

Roots Analysis

MAY 21, 2024

These are the vital structural component of cells, which help in cell functioning and regulation of building body tissues. However, continuous regulation of the cellular proteome is essential for maintaining the right balance of different proteins necessary for normal cellular function, survival, and proliferation.

Protein 40

Protein Marketing Development Antibody 40

XTalks

MAY 11, 2023

Now it’s regulators, payers, academics, patient communities, physicians and industry all asking, “Where have you incorporated the patient voice? Moreover, we embed patient centricity far beyond clinical development. Development is just the beginning. Where have you asked caregivers about what really matters?

Clinical Trials 97

Clinical Trials Clinical Trials Trials Development 97

Delveinsight

AUGUST 25, 2021

The pharmaceutical industry finds, develops, manufactures, and promotes medicines or pharmaceutical drugs for usage as medications that are administered (or self-administered) to patients in order to cure, vaccinate, or relieve symptoms. Pharmaceutical companies may deal in both generic and brand-name drugs as well as medical devices.

Vaccine 98

Vaccine Vaccination Drugs Sales 98

The Pharma Data

NOVEMBER 5, 2020

The demand for an effective drug for nail fungus is high and MOB-015 can achieve a unique market position through its high antifungal effect,” says Anna Ljung, CEO of Moberg Pharma. The information was submitted for publication, through the agency of the contact persons set out above, at 8.00 CET on November 6, 2020.

Marketing 40

Marketing Production Regulation Containment 40

XTalks

MARCH 11, 2025

The Current State of mRNA Analytics There isnt a lot of emphasis right now being put on new method development specifically for application to multivalent mRNA vaccines. And I think this is surprising given just how many multivalent mRNA vaccines are currently in clinical development, begins Dr. Dawson.

Vaccination 64

Vaccination Vaccine Development Manufacturing 64

The Pharma Data

DECEMBER 16, 2020

Recombinant monoclonal antibodies are designed to enhance the immune system’s ability to regulate cell functions. The company currently plans to include more than 4,000 participants in additional trials, which it believes could support an initial regulatory approval as soon as the fourth quarter of 2021. government in September.

Vaccination 52

Vaccination Vaccine DNA Antibody 52